PegIFN alfa-2b

DRUG3 trials

Sponsors

Foundation for Liver Research, Merck Sharp & Dohme LLC, Huashan Hospital

Conditions

Chronic Hepatitis BMalignant Melanoma

Phase 1

A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370)

TerminatedNCT01636960

Merck Sharp & Dohme LLCMalignant Melanoma

Start: 2012-12-25End: 2015-11-04Updated: 2018-08-08

Phase 4

Lowering Viral Load With Nucleos(T)Ide Analogues Prior to Peginterferon Treatment to Ncrease Sustained Response in CHB

CompletedNCT01532843

Foundation for Liver ResearchChronic Hepatitis B

Start: 2012-06-30End: 2015-08-31Updated: 2019-01-04

Pegylated Interferon Alfa-2b in Reducing Relapse Rates After Nucleos(t)ide Analogue Withdrawal in HBeAg-negative CHB Patients with Low Level HBsAg

Not yet recruitingNCT06900166

Huashan HospitalChronic Hepatitis B

Start: 2025-04-01End: 2029-04-30Target: 360Updated: 2025-03-28

Related Papers

Levels of Antibodies to Hepatitis B Core Antigen Are Associated With Liver Inflammation and Response to Peginterferon in Patients With Chronic Hepatitis B

The Journal of Infectious Diseases2022-05-2319 citations

Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B

Alimentary Pharmacology & Therapeutics2019-01-2831 citations

Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON)

The Journal of Infectious Diseases2017-03-0254 citations